西南国防医药2018，Vol.28Issue(3)：228-230,3.DOI:10.3969/j.issn.1004-0188.2018.03.010
卡培他滨联合化疗治疗HER-2阴性晚期乳腺癌的效果观察
Observation on curative effects of Capecitabine combined with chemotherapy on HER-2 negative advanced breast cancer
郑晨晨1
作者信息
- 1. 442000湖北十堰,十堰市妇幼保健院检验科
- 折叠
摘要
Abstract
Objective To explore the curative effect of Capecitabine combined with chemotherapy on HER-2 negative advanced breast cancer.Methods A total of 112 HER-2 negative advanced breast cancer patients having failed in the Taxanes and Anthracycline treatments and having been admitted into our hospital were randomly divided into two groups (n=56,respectively).Capecitabine combined with cis-platinum treatment was performed on the patients in the XP group and Capecitabine combined with Docetaxel was performed on the patients in the TX group.Both groups took 21 days as one period of chemotherapy and at least two periods were performed.The near-term curative effects,PFS,OS and toxic reactions of chemotherapy in the two groups were researched.Results The XP group had a DCR of 69.64％,higher than that in the TX group of 50.0％(P ＜ 0.05);PFS and OS in the XP group were separately 7.2 and 17.6 months,longer than those in the TX group (5.7 and 14.1 months separately) (P＜ 0.05);the XP group showed a lower incidence of hair loss than the TX group (P ＜ 0.05).There were no statistical differences in the incidence of toxic reactions between the two groups (P ＞ 0.05).Conclusin The near-term curative effects on HER-2 negative advanced breast cancer that has failed in the Taxanes and Anthracycline treatments of the XP scheme are better than that of the TX scheme.关键词
乳腺癌/HER-2阴性/卡培他滨/联合化疗/疗效Key words
breast cancer/HER-2 negative/Capecitabine/combined chemotherapy/curative effect分类
医药卫生引用本文复制引用
郑晨晨..卡培他滨联合化疗治疗HER-2阴性晚期乳腺癌的效果观察[J].西南国防医药,2018,28(3):228-230,3.
